Sort
39,280 grants matching “leukemia”
The switch between epigenetically silenced and active chromatin states
$297,297Vincenzo Pirrotta · Rutgers, The State Univ Of N.J. · R01 · FY2011 · GM
Novel Biologically Targeted Therapy Against the Mer and Axl Receptor Tyrosine Kin
$297,284Douglas K Graham · University Of Colorado Denver · R01 · FY2012 · CA
ANIMAL MODELS OF MOLECULAR PATHOGENSIS OF HTLV-1
$297,273Ohio State University · R01 · FY2000 · RR
Analysis of a murine model of the AML1-ETO translocation
$297,250University Of Alabama At Birmingham · R01 · FY2005 · CA
Analysis of a murine model of the AML1-ETO translocation
$297,250University Of Alabama At Birmingham · R01 · FY2004 · CA
Genes Controlling Blood Cell Development in Drosophila
$297,237Robert A. Schulz · University Of Tx Md Anderson Can Ctr · R01 · FY2007 · HL
PROTOCOL REVIEW AND MONITORING SYSTEM
$297,208Thomas G. Budd · Case Western Reserve University · P30 · FY2010 · CA
Physiological Factors in Hyperthermia
$297,189University Of Minnesota Twin Cities · R01 · FY2003 · CA
Role of the STK Receptor in Erythropoiesis
$297,176Pamela A Hankey · Pennsylvania State University, The · R01 · FY2008 · HL
Clinical Trial Office
$297,138John C Byrd · Ohio State University · P30 · FY2007 · CA
COGNITIVE BEHAVIORAL ASPECTS OF CANCER RELATED FATIGUE
$297,109University Of South Florida · R01 · FY2000 · CA
Colorectal Cancer Molecular Subtype Assay Development and Validation
$297,095Dipen M. Maru · University Of Tx Md Anderson Can Ctr · UH3 · FY2021 · CA
Mechanisms of Anticancer Agents Selective against Drug Resistant Leukemia
$297,092Chengguo Xing · University Of Minnesota · R01 · FY2014 · CA
Synthetic Biology for Splice Modulating Polyketides
$297,088David Alan Mead · Varigen Biosciences Corporation · R43 · FY2024 · CA
Development of SHP2-selective Phosphatase Inhibitors for Cancer Therapy
$297,067Jie Wu · H. Lee Moffitt Cancer Ctr & Res Inst · P01 · FY2010 · CA
Flavopiridol and Imatinib in Bcr/Abl+ Leukemia
$297,053Virginia Commonwealth University · R21 · FY2003 · CA
Characterization and drug targeting of the PML tumor suppressor in lung cancer
$297,042Pier P Scaglioni · Ut Southwestern Medical Center · R01 · FY2013 · CA
GENETICS OF RESISTANCE TO LEUKEMIA
$297,039New York University School Of Medicine · R01 · FY2000 · CA
Control of lymphoid effector programs by the E3 ligase cullin 3
$297,026Albert S. Bendelac · University Of Chicago · R01 · FY2014 · GM
Control of lymphoid effector programs by the E3 ligase cullin 3
$297,026Albert S. Bendelac · University Of Chicago · R01 · FY2015 · GM
Control of lymphoid effector programs by the E3 ligase cullin 3
$297,026Albert S. Bendelac · University Of Chicago · R01 · FY2016 · GM
Control of lymphoid effector programs by the E3 ligase cullin 3
$297,026Albert S. Bendelac · University Of Chicago · R01 · FY2013 · GM
Cell Cycle Abnormalities in Thymic Malignancy
$297,010Piotr Sicinski · Dana-Farber Cancer Inst · P01 · FY2008 · CA
Liver Vs Bone PAH Metabolism: Synergy with TNF in Bone
$297,010Colin Robert Jefcoate · University Of Wisconsin-Madison · R01 · FY2009 · DK
Liver Vs Bone PAH Metabolism: Synergy with TNF in Bone
$297,010Colin Robert Jefcoate · University Of Wisconsin-Madison · R01 · FY2008 · DK